GSK joins the National Pharmaceutical Council
WASHINGTON British drug maker GlaxoSmithKline is the latest company to join health policy research organization the National Pharmaceutical Council, the NPC announced Thursday.
Established in 1953, the NPC sponsors and conducts scientific analyses of the use of drugs with support from drug companies. GlaxoSmithKline SVP private, public and institutional customers Jack Bailey will serve as the company’s representative on the NPC’s board of directors.
“As the nation moves forward with the implementation of healthcare reform, NPC’s research provides policy makers and implementers with keen insight on comparative effectiveness research and health-and-wellness issues,” Bailey said. “I welcome the opportunity to work with NPC and its staff as they move forward with these and other research areas impacting the pharmaceutical industry.”
Reaching out to new CMS administrator Berwick, NACDS highlights pro-patient, pro-pharmacy goals
ALEXANDRIA, Va. The National Association of Chain Drug Stores is moving quickly to establish a working relationship with newly installed Medicare and Medicaid chief Donald Berwick.
NACDS on Wednesday sent a letter to Berwick, who was tapped by President Obama to serve as the new administrator of the Centers for Medicare & Medicaid Services. NACDS president and CEO Steve Anderson urged continued collaboration with CMS on issues related to pharmacy that he said are vital to quality health care and cost reduction.
“NACDS and its member companies are committed to improving patient adherence to their prescription drug regimens,” Anderson told Berwick. “We strongly believe that access to neighborhood pharmacies and pharmacist-provided care can improve health outcomes for patients and reduce costs.”
Anderson also pointed to issues of major concern to retail pharmacy, including fair reimbursement for prescription and pharmacy services, pharmacy’s role in a medical home and the prevention of fraud, waste and abuse. He pledged NACDS’ support in working with the new CMS chief on ongoing efforts to reduce fraud and waste in the healthcare system.
“We look forward to working with you on these and other issues that impact chain pharmacies and the patients they serve,” the letter concluded.
Eli Lilly acquires Alnara
INDIANAPOLIS Drug maker Eli Lilly has finished its acquisition of a company developing a pancreatic disorder treatment.
Lilly announced Tuesday that it had finished acquiring Alnara Pharmaceuticals, a privately held company, in a deal announced July 2. Lilly acquired Alnara for an upfront payment of $180 million, and Alnara stockholders could receive up to $200 million in additional milestone payments based on product performance.
Alnara is developing liprotamase, a pancreatic enzyme replacement therapy under review by the Food and Drug Administration as a treatment for exocrine pancreatic insufficiency, a disease resulting from cystic fibrosis, removal of the pancreas, chronic pancreatitis and other conditions.